Storia in 6 fonti

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics

Capricor stock plunged after an FDA panel questioned Deramiocel's effectiveness in DMD despite published Phase 3 HOPE-3 trial results.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.com3 g fa

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor stock falls 61% as FDA challenges Deramiocel efficacy; Phase 3 DMD trial missed primary endpoint, cardiac data show no benefit. Signal for biotech acquirers: late-stage efficacy gaps elevate regulatory risk, erode valuations, tighten clinical M&A discipline.

Leggi questa versione → originale

Timeline cronologica

lunedì 27 luglio 2026·medpagetoday.com
FDA Scientists Raise Questions About Duchenne Drug
Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data
lunedì 27 luglio 2026·benzinga.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics

Confronto fonti

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Timeline cronologica

FDA Scientists Raise Questions About Duchenne Drug

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor Duchenne cell therapy voted down by FDA panel

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor…

FDA expert panel recommends against approval of Capricor’s Duchenne drug

FDA Committee Votes Down Duchenne Drug

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…

Capricor Duchenne cell therapy voted down by FDA panel

FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

FDA expert panel recommends against approval of Capricor’s Duchenne drug

FDA Committee Votes Down Duchenne Drug

FDA and Capricor clash over deramiocel efficacy data at Duchenne adcomm vote

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics

CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities…

CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.

CAPR CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Capricor Therapeutics, Inc.